X-Magtech Completes Series B Financing of Several Hundred Million RMB, Accelerating Commercialization of Quantum Biomagnetic Field Measurement

In June 2026, X-Magtech announced the completion of a Series B financing round totaling several hundred million RMB. New investors in this round primarily include Beijing Quantum Fund, Beijing Medical and Health Fund, Beijing State-owned Capital Operation and Management, Beijing Jingguosheng Investment, and Cornerstone Venture Capital. Existing shareholder Casstar also participated in this round.

This financing represents the largest disclosed single financing round globally in the field of quantum magnetic field measurement. It marks a strong endorsement by the capital market of X-Magtech's core technologies, product portfolio, and commercialization progress, further consolidating the company's global leading position in the commercialization of quantum magnetic field measurement. The proceeds from this financing round will be used to accelerate the iterative development of core technologies, scale up mass production, and drive the industrialization of additional application scenarios.

The "15th Five-Year Plan" explicitly identifies quantum technology as a key priority for future industries. Quantum precision measurement, as the core branch that has taken the lead in achieving commercial breakthroughs, has already formed clear pathways for implementation in fields such as advanced medical care, brain science, and industrial inspection. X-Magtech is addressing critical clinical needs with helium-free, room-temperature, and non-invasive biomagnetic measurement equipment, driving quantum technology from the laboratory to medical institutions, research institutes, and global markets.

This financing round brings together high-quality capital from key Beijing municipal industry funds and national-level hard technology investment platforms, forming a synergistic ecosystem of "quantum industry funds, medical and health funds, state-owned capital, and market-driven hard technology institutions." This represents not only the capital market's recognition of X-Magtech's technological roadmap, engineering capabilities, and commercialization progress, but will also provide systematic support for the company's development of core components, scaling of mass production, expansion across hospital networks throughout China, and global market access.

X-Magtech's core technological pathway for its atomic magnetometer is based on leveraging changes in the quantum state of electron spins in neutral atoms to achieve ultra-sensitive detection of external magnetic fields. Compared with conventional superconducting routes, this technology operates at room temperature without the need for liquid helium, eliminating the requirement for expensive liquid helium supply and complex cryogenic systems. This significantly lowers the barriers to deployment and maintenance for hospitals, while also offering multi-channel, high-density array scalability.

At present, X-Magtech's commercially available atomic magnetometer has consistently achieved a detection sensitivity on the order of 10 femtotesla (fT). The company has established fully independent, end-to-end capabilities covering core sensors, magnetic shielding, signal acquisition, intelligent algorithms, and complete system integration. Horizontally, X-Magtech has expanded its product portfolio to include magnetocardiography (MCG), magnetoencephalography (MEG), combined MCG/MEG systems, and magnetogastrography (MGG), thereby building a biomagnetic field measurement platform applicable to multiple organs, disease types, and clinical scenarios.

At the 2026 China Association of Medical Equipment, X-Magtech unveiled the Marvel MEG® Max 312-channel helium-free magnetoencephalography (MEG) system and a 512-channel, four-person hyperscanning system successfully commercialized and installed at Tsinghua University. Both systems have set new industry benchmarks in the global clinical and research MEG landscape, demonstrating X-Magtech's continued breakthroughs and innovation capabilities in core sensor chipization, system integration, mass production consistency, and the engineering of complex medical equipment.

The ultra-high-channel, interactive multi‑person MEG system provides clinical and research users with higher‑density signal acquisition capabilities and greater application flexibility. It holds significant potential in areas such as lesion localization, functional brain mapping and assessment, fundamental brain science research, and brain‑computer interface exploration.

Leveraging its core quantum precision measurement technology and full-chain independent capabilities, X-Magtech has taken the lead in undertaking a number of major national-level projects, including the "Development of Novel Helium-Free Magnetoencephalography System" under the 14th Five-Year National Key R&D Program, the "Quantum + Medical Detection" project under the Ministry of Industry and Information Technology (MIIT) Future Industry Innovation Open Competition, the "Brain Magnetic Imaging Equipment" project as part of the high-end medical equipment promotion initiative jointly launched by the MIIT, the National Health Commission (NHC), and the National Medical Products Administration (NMPA), and the "Intelligent Auxiliary Diagnostic Software for Myocardial Ischemia Using Magnetocardiography" project under the MIIT and NHC Artificial Intelligence Medical Device Innovation Initiative. The implementation of these national projects has not only provided top-level policy support and resources for the company's core technology breakthroughs and clinical translation of its products, but has also facilitated the establishment of a technical standard system for quantum medical technology, accelerating the development of domestically produced high-end medical equipment.

X-Magtech has completed installations and established a collaborative industry-research-medicine network at dozens of national medical centers and clinical research centers, as well as over 20 leading hospitals, universities, and research institutes, covering fields such as neurological disorders, mental health, cardiovascular medicine, pediatric medicine, brain science, and cognitive neuroscience. Through close collaboration with clinical and research experts, the company has accumulated over 100,000 clinical data points within just two years and has published more than 30 high-impact scientific articles. These achievements have fully validated the accuracy and effectiveness of magnetocardiography (MCG) and magnetoencephalography (MEG) in clinical applications, including the diagnosis of cardiovascular diseases, preoperative localization of epileptic foci, and motor cortex mapping. Furthermore, X-Magtech has successfully explored innovative applications in areas such as magnetogastrography, artificial intelligence algorithm integration, language function decoding, psychiatric disorder assessment, and non-invasive brain-computer interfaces. It has achieved multiple world-first research outcomes, application scenarios, and technical specifications, continuously accelerating the commercialization of its MCG and MEG products.

Following the completion of this financing round, X-Magtech will continue to deepen its core research and development in quantum precision magnetic field sensing and high-end medical equipment. The company will further enhance its standardized mass production system, improve delivery capabilities for both core components and complete systems, and accelerate the large-scale deployment of its products in medical institutions, universities, and research institutes, promoting the evolution of domestically produced quantum high-end medical equipment from "functional" to "user-friendly, scalable, and broadly accessible."

On the global front, X-Magtech will advance the overseas registration, international clinical certification, and standardization of its entire product portfolio. By exploring commercialization opportunities in high-end medical and cutting-edge brain science research markets worldwide, the company aims to transition China's quantum precision measurement technology from domestic substitution to a globally recognized brand.